1. Introduction {#sec1}
===============

Mutations in the *parkin* gene (*PARK2*) are considered to be the predominant cause of early-onset Parkinson disease particularly when the family history is compatible with autosomal recessive inheritance \[[@B1]\]. This condition is characterized by early onset of disease, usually before the age of 40 years, dystonia, sleep benefit, early complications from levodopa treatment, and slow progression. *Parkin*-associated tremor-dominant parkinsonism includes a spectrum of late-onset disorders without manifestations of foot dystonia, hyperreflexia, diurnal fluctuations, sleep benefit, or early susceptibility to levodopa-induced dyskinesia \[[@B2]\]. Therefore, patients with *PARK2* mutations are often clinically indistinguishable from those with sporadic Parkinson\'s disease (PD).

PD patients exhibit decreased myocardial uptake of meta-iodobenzylguanidine (MIBG) during ^123^I-MIBG myocardial scintigraphy---a finding indicative of cardiac sympathetic denervation \[[@B3]\]. Olfactory impairment, an early symptom of PD, occurs in more than 70% of patients with PD \[[@B4]\]. Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by a loss of normal skeletal muscle atonia and complex motor activity, specifically during REM sleep associated with dream mentation. Thirty-eight percent of RBD patients aged ≥ 50 years were eventually diagnosed with PD \[[@B5]\]; therefore, RBD may serve as an early indicator of PD.

Here, we examined nonmotor symptoms in patients with *PARK2* mutations.

2. Methods {#sec2}
==========

Mutation of the parkin gene was confirmed by gene analysis \[[@B1]\]. Eight women and 7 men possessed mutations in the *PARK2* gene: cases 1, 2, 3, 8, and 13 carried homozygous-deletions, and the remaining carried heterozygous mutations or deletions ([Table 1](#tab1){ref-type="table"}). Clinical findings and medications are shown in [Table 1](#tab1){ref-type="table"}.

The MIBG study involved 6 women and 7 men (mean (SD) age, 58.5 (11.4) years) with *PARK2* mutations: 5 subjects had homozygous deletions, and 8 had heterozygous mutations or deletions. Patients had parkinsonism for a mean (SD) period of 22.0 (11.59) years (range, 10--44 years). When MIBG scintigraphy was performed, the patients were not medicated with monoamine oxidase B (MAOB) inhibitors, selective serotonin reuptake inhibitors, or antidepressant drugs. Data was collected by E CAM at 30 minutes and 3 hours after injection of ^123^I-MIBG (MyoMIBG-I 123 injection, 111 MBq; FUJIFILM RI Pharma Co. Ltd.). The cut-off ratio of the heart to mediastinum (H/M) uptake ratio of ^123^I-MIBG in our hospital was set at 1.45.

The olfactory function and polysomnography (PSG) study involved 3 women and 3 men (mean (SD) age, 47.8 (13.2) years) with *PARK2* mutations ([Table 1](#tab1){ref-type="table"}).

The mean olfactory function scores of the PD patients and 10 age-matched Japanese controls, who were evaluated for comparison with patients with *PARK2* mutations, were determined by the Sniffin\' Sticks test. Mean age of the controls without neurological disease or dementia was 46.0 (15.3) years (range, 39--79 years). The PD patients (mean age, 69.6 (6.6) years; range, 60--89 years; not age matched to patients with *PARK2* mutations) fulfilled the UK Brain Bank criteria for possible or probable clinical PD, with Hoehn-Yahr stages II and III without dementia.

Olfactory testing was examined by following 3 components. Olfactory threshold and odor discrimination and identification were investigated in 3 separate substrates using standardized Sniffin\' Sticks \[[@B6]\]. Sniffin\' Sticks are commercially available felt-tip pens.

Odor ThresholdsThe olfactory threshold subset consisted of 16 Sniffin\' Stick triplets with different concentrations of *n-*butanol. Three sticks were presented to the subject in randomized order. Two contained only the solvent and the third the odorant at a particular dilution. The subjects were tasked to identify the stick with the odorant.

Odor DiscriminationIn the odor discrimination subset, 16 Sniffin\' Stick triplets were presented in randomized order. Two pens contained the same odorant and the third a different odorant. The task was to identify the stick that had the different smell.

Odor IdentificationThe third subtest consisted of 16 single sticks and assessed the ability to identify an odor. Using a multiple-choice task, identification of individual odorants was performed from a list of 4 descriptors.

RBD was confirmed by studying the patients\' clinical history and video-PSG findings (International Classification of Sleep Disorders, 2nd edition) \[[@B7]\].

Informed consent was obtained from patients with*PARK2* mutations, and patients with PD, and normal volunteers.

The data was statistically analyzed using SPSS ver.11 for Windows.

3. Results {#sec3}
==========

The mean H/M uptake ratio of ^123^I-MIBG scintigraphy in *PARK2* patients was 1.79 (0.31) in the early phase and 1.75 (0.51) in the delayed phase ([Table 2](#tab2){ref-type="table"}). However, a 58-year-old woman, with a 10-year disease duration and orthostatic hypotension and constipation without myocardial damage, exhibited accelerated MIBG elimination (H/M ratio: early, 1.23; delayed, 1.15). Three patients (cases 2, 7, and 12) had exhibited slightly decreased uptake in the delayed phase.

The Sniffin\' Sticks test revealed a slight olfactory dysfunction with the following mean scores in examined *PARK2* patients ([Table 3](#tab3){ref-type="table"}): threshold score, 6.1 (1.6) (*P* \< .05 when compared with controls); odor discrimination score, 10.0 (2.4); odor identification score, 10.1 (4.8) (no significant differences when compared to controls). Odor discrimination and identification functions were not impaired in any of the patients with *PARK2* mutations, except in patient 1. In the Japanese examined normative controls, the mean olfactory function scores were as follows: threshold score, 8.0 (1.3); discrimination score, 11.9 (2.4); identification score, 10.9 (2.0); in PD patients, these mean scores were 2.2 (6.6), 6.1 (2.5), and 5.1 (1.8), respectively.

PSG did not reveal tonic responses in the mentalis and tibialis muscles during REM ([Table 3](#tab3){ref-type="table"}). Twitching of the tibialis muscle was observed in 2 patients. None of the patients with *PARK2* mutations met the ICSD-II criteria for RBD.

4. Discussion {#sec4}
=============

Decreased ^123^I-MIBG uptake was observed clearly in 1 patient with *PARK2* mutations who had autonomic dysfunction. Early phase myocardial uptake of MIBG in all of the other patients showed no decrease, and patients had no autonomic dysfunction. Similar to our study, in a previous study \[[@B8]\], 1 of 4 patients with *PARK2* mutations with a 12-year disease duration and unclear autonomic dysfunction exhibited decreased uptake of ^123^I-MIBG. Additionally, 3 patients in our study who showed decreased ^123^I-MIBG uptake were slightly older than the other patients, although a significance in mean age (63.0 (9.1) versus 55.9 (10.8); *P* \> .05) did not exist. Estorch et al. and Tsuchimochi et al. reported that the uptake of ^123^I-MIBG decreased with age, suggesting that aging could affect patients with *PARK2* mutations \[[@B9], [@B10]\]. Decreased myocardial uptake of MIBG is considered to indicate the presence of alpha-synuclein aggregates in the axons in PD \[[@B11]\]. In MIBG-myocardial scintigraphy, the H/M ratio of patients with *PARK2* mutations was reported to be within the range of the normal controls \[[@B12]\]. Moreover, postmortem examination of patients with *PARK2* mutations revealed that tyrosine hydroxylase immunoreactive nerve fibers in the epicardium were well preserved \[[@B13]\]. These findings might reflect normal functioning myocardial sympathetic nerve terminals in patients with *PARK2* mutations. MIBG scintigraphy might be a marker for alpha-synuclein in patients with *PARK2* mutations; however, there are no pathological reports on the presence of Lewy bodies in patients with *PARK2* mutations exhibiting decreased MIBG uptake.

Olfactory impairment is a nonmotor symptom of PD. We found that the olfactory threshold was slightly higher in patients with *PARK2* mutations than in controls. The oldest woman in our study, who did not have dementia, exhibited the highest degree of olfactory impairment. Although in self-completed questionnaire study, 3 of 16 patients with *PARK2* mutation had loss of taste/smell \[[@B14]\]. However, in previous studies, individuals with *PARK2* mutations were found to have normal olfactory function \[[@B15], [@B16]\]. The discrepancy between our results and previous ones may be because previous studies used the Pennsylvania Smell Identification Test, which does not include the threshold test. In Kahn\'s study \[[@B15]\], the odor identification score did not significantly differ between patients with *PARK2* mutations and controls, although this did not necessarily imply that the threshold score was normal in the patients.

PSG did not reveal RBD in any of our patients. However, in a study by Kumru et al., 6 of 10 patients had RBD \[[@B17]\]. We cannot explain this discrepancy, but we hypothesize that it may be due to the differences in patient mean age between the 2 studies. Some of our patients with *PARK2* mutations have twitching in the tibialis muscle; therefore, the possibility that they will eventually develop RBD cannot be ruled out. Neuropathological studies on patients with *PARK2* mutations have revealed neuronal loss and gliosis in the pars compacta of the substantia nigra and in the locus coeruleus \[[@B18]\]. However, these studies have not described the state of the subcoeruleus nucleus, which is considered the primary site affected in RBD.

The results obtained in this study suggest that some patients with *PARK2* mutations have increased thresholds of olfactory function and myocardial sympathetic dysfunction as nonmotor symptoms. We might show that the nonmotor symptoms of *PARK2*were impaired heterogeneously.
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###### 

Clinical findings and medication of patients with PARK2 mutation.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case                     1                         2                      3                         4                        5                                     6                         7                         8                     9                              10                          11                       12                          13                          14
  ------------------------ ------------------------- ---------------------- ------------------------- ------------------------ ------------------------------------- ------------------------- ------------------------- --------------------- ------------------------------ --------------------------- ------------------------ --------------------------- --------------------------- ------------------------
  Age sex                  71 F                      55 M                   46 M                      41 F                     38 M                                  36 F                      76 M                      70 M                  63 M                           61 F                        61 F                     60 F                        57 M                        44 F

  Parkin                   exon 2--4 homo deletion   exon 5 homo deletion   exon 6, 7 homo deletion   exon 6 hetero deletion   exon 4, intron 4 accepter site, A→G   exon 10 hetero mutation   exon 10 hetero mutation   exon 2 homodeletion   exon 2, 3, 4 hetero deletion   exon 2, 3 hetero deletion   exin 4 hetero deletion   exon 3, 4 hetero deletion   exon 2, 3, 4 homodeletion   exon 5 hetero deletion

  On set                   61                        28                     28                        27                       18                                    20                        65                        45                    33                             29                          47                       16                          45                          34

  Disease duration         10                        27                     18                        14                       20                                    16                        11                        28                    36                             34                          14                       44                          12                          10

  Family history           −                         \+                     \+                        −                        −                                     \+                        \+                        −                     −                              \+                          −                        \+                          \+                          \+

  Hoehn & Yahr\            2                         2                      2                         1                        1.5                                   2                         2                         3                     3                              3                           3                        3                           1                           1
  stage on                                                                                                                                                                                                                                                                                                                                                                                 

  Rigidity\*               1                         1                      0                         1                        2                                     0                         1                         0                     0                              1                           0                        0                           0                           0

  Tremor\*                 1                         0                      0                         1                        0                                     0                         1                         1                     0                              0                           0                        0                           0                           0

  Hesitation\*             0                         1                      1                         0                        0                                     2                         0                         1                     1                              2                           2                        1                           0                           0

  Wearing-off              \+                        \+                     \+                        −                        \+                                    \+                        −                         \+                    \+                             \+                          \+                       −                           \+                          −

  Dementia                 −                         −                      −                         −                        −                                     +\*\*                     −                         −                     −                              −                           −                        −                           −                           −

  Hallucination            −                         −                      −                         −                        −                                     \+                        −                         −                     −                              −                           \+                       −                           −                           −

  Sleep violent behavior   −                         −                      −                         −                        −                                     −                         −                         −                     −                              −                           −                        −                           −                           −

  Constipation             +\*\*\*                   −                      −                         −                        −                                     −                         −                         −                     −                              −                           \+                       −                           −                           −

  Levodopa                 700 mg                    600 mg                 600 mg                    300 mg                   400 mg                                300 mg                    −                         300 mg                500 mg                         995 mg                      800 mg                   200 mg                      450 mg                      −

  Agonist\                 pramipexole 1.5 mg        pramipexole 4.5 mg     pramipexole 3 mg          ropinirole 9 mg          pramipexole 1.5 mg                    ropinirole 12 mg          pramipexole 4.5 mg        −                     pramipexole 0.75 mg            pramipexole 1.5 mg          pramipexole 2.25 mg      ropinirole 16 mg            −                           pramipexole 1.5 mg
  non-ergot                                                                                                                                                                                                                                                                                                                                                                                

  Agonist ergot            −                         pergolide 2.25 mg      −                         −                        cabergoline 4 mg                      −                         −                         −                     −                              −                           −                        −                           cabergoline 2 mg            −

  Selegiline               −                         5 mg                   −                         −                        10 mg                                 5 mg                      −                         −                     −                              −                           5 mg                     −                           2.5 mg                      −

  Entacapone               −                         400 mg                 600 mg                    −                        300 mg                                600 mg                    −                         −                     400 mg                         −                           −                        −                           −                           −

  Trihexyphenidyl          −                         −                      −                         −                        3 mg                                  −                         −                         5 mg                  −                              −                           −                        −                           −                           −

  Amantadine               300 mg                    150 mg                 300 mg                    −                        300 mg                                −                         −                         −                     150 mg                         200 mg                      100 mg                   300 mg                      −                           −
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DID: dopa induced dyskinesia.

\*UPDRS mean score \*\*Thalamotomy \*\*\*no medication.

###### 

The findings of ^123^IMIBG myocardial scintigraphy in PARK2 patients.

  Case           1      2      3      5      7      8      9      10     11     12     13     14     average ± SD
  -------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ --------------
  Examined age   65     55     46     41     76     70     63     61     61     60     57     44     58.3 ± 10.5
  Early H/M      2.27   1.64   1.91   1.75   1.52   2.05   1.75   1.66   1.23   1.75   1.62   2.35   1.79 ± 0.31
  Delay H/M      2.14   1.33   1.67   1.93   1.34   2.93   1.65   1.54   1.15   1.40   1.60   2.35   1.75 ± 0.51

H/M: the heart to mediastinum uptake ratio of ^123^IMIBG.

###### 

Olfactory function by Sniffin\' sticks and PSG study in patients with PARK2 mutation, controls, and Parkinson\'s disease.

  Case                                  1      2      3      4      5      6      *PARK2* total (*n* = 6)   Control (*n* = 10)   Parkinson\'s disease (*n* = 15)
  ------------------------------------- ------ ------ ------ ------ ------ ------ ------------------------- -------------------- ---------------------------------
  Age                                   71     55     46     41     38     36     47.8 ± 13.2               46.0 ± 15.3          69.6 ± 6.6
  Sniffin\' sticks Test                                                                                                          
  Threshold test                        4.5    6.3    6.3    5.8    5.0    9.0    6.1 ± 1.6                 8.0 ± 1.3\*          2.2 ± 2.3\*\*
  Discrimination test                   8.0    9.0    12.0   14.0   9.0    8.0    10.0 ± 2.4                11.9 ± 2.4           6.1 ± 2.5
  Identification test                   1.0    13.0   10.0   14.0   13.0   10.0   10.1 ± 4.8                10.9 ± 2.0           5.1 ± 1.8
                                                                                                                                 
  PSG findings                                                                                                                   
  Apnea index (times/H)                 10.1   22.5   1.2    0.4    1.0    2.1                                                   
  Hypopnea index (times/H)              2.2    14.0   4.7    0.3    1.9    9.4                                                   
  Apnea Hypopnea index (times/H)        12.3   36.5   5.9    0.8    3.0    11.4                                                  
  Arousal index (times/H)               16.0   39.8   37.7   13.4   14.3   11.1                                                  
  Respiratory arousal index (times/H)   5.5    27.3   4.6    0.2    1.6    3.3                                                   
  PLM index(times/H)                    7.8    0.0    7.7    0.0    29.5   0.0                                                   
  PLM arousal index(times/H)            0.0    0.0    5.3    0.0    2.8    0.0                                                   
  REM sleep twitching on TA muscle      −      \+     −      \+     −      −                                                     

H/M: theheart to mediastinum uptake ratio, NE: not examined.

PLM: periodic limb movements, TA: tibialis anterior.

\**t*-test: compared with*PARK2* patients *P* \< .05.

\*\**t*-test: compared with *PARK2* patients and control *P* \< .01.
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